
## Roni Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2025650/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes ( <scp>LIVE</scp> )—a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
2	Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 2019, 139, 2129-2141.	1.6	289
3	Ketone Body Infusion With 3â€Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study. Journal of the American Heart Association, 2017, 6, .	3.7	144
4	Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1220-H1225.	3.2	34
5	Effect of Blood Flow Restricted Resistance Exercise and Remote Ischemic Conditioning on Functional Capacity and Myocellular Adaptations in Patients With Heart Failure. Circulation: Heart Failure, 2019, 12, e006427.	3.9	33
6	Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	32
7	Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. Journal of Nuclear Cardiology, 2018, 25, 169-176.	2.1	32
8	Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	24
9	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq1	10.71894314	1 rg₿∑ /Overlo
10	Failing Heart of Patients With Type 2 Diabetes Mellitus Can Adapt to Extreme Short-term Increases in Circulating Lipids and Does Not Display Features of Acute Myocardial Lipotoxicity. Circulation: Heart Failure, 2013, 6, 845-852.	3.9	20
11	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
12	Effect of Acute Hyperglycemia on Left Ventricular Contractile Function in Diabetic Patients with and without Heart Failure: Two Randomized Cross-Over Studies. PLoS ONE, 2013, 8, e53247.	2.5	17
13	The impact of the glucagonâ€like peptideâ€l receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
14	Test–retest repeatability of myocardial oxidative metabolism and efficiency using standalone dynamic 11C-acetate PET and multimodality approaches in healthy controls. Journal of Nuclear Cardiology, 2018, 25, 1929-1936.	2.1	15
15	Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Research and Care, 2016, 4, e000202.	2.8	13
16	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
17	Myocardial efficiency in patients with different aetiologies and stages of heart failure. European Heart Journal Cardiovascular Imaging, 2022, 23, 328-337.	1.2	8
18	Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure. Pulmonary Circulation, 2018, 8, 1-7.	1.7	6

#	Article	IF	CITATIONS
19	Clinical use of cardiac 18ÂF-FDG viability PET: a retrospective study of 44 patients undergoing post-test revascularization. International Journal of Cardiovascular Imaging, 2022, 38, 2447-2458.	0.6	1